SheMed Weight Loss Programme: Clinical Study

The SheMed Weight Loss Programme does more than help our members shed pounds. It also serves as a ground-breaking clinical study aimed at uncovering how GLP-1s can address other key women’s health conditions.

Why are we doing this clinical study?

GLP-1 medications have historically been used to treat diabetes and obesity. However, very few studies have explored the extent to which GLP-1 medications could effectively address specific women’s health conditions, like the ones listed below.

Menopause

Perimenopause

Endometriosis

PCOS

What we hope to achieve

We aim to uncover definitive evidence and valuable insights through this clinical study, showcasing how GLP-1 medications can effectively address women’s health conditions while empowering them to achieve their weight loss goals.

From a healthcare perspective, this success could be a game-changer, paving the way to close the significant care and treatment gap that women’s health has long faced compared to other medical fields.

Key information

How does the SheMed Weight Loss Programme work?
The Programme is designed to deliver a high-adherence model of care, offering support and guidance to participants throughout their weight loss journey. As part of the process, we prioritise valuable health insights and safety, ensuring eligibility and ongoing monitoring to help participants succeed while staying healthy.

How do you use each participant’s data and personal information?
All data is anonymised. We do not sell or or share any individual’s data to any other company or person. Our sole aim with this clinical study is to learn and share key findings and research about the relationship between GLP-1 medications and women’s health conditions, which we hope in turn will help close the women's health gap.

Who can participate?
Adults between the ages of 18 and 75 who meet the eligibility criteria and live in England or Wales. Participants agree to the normal terms of the Programme, including any monthly fee associated.

What does the study involve?
The Programme involves regular check-ins including weight, side effect monitoring, blood tests and questionnaires. This data will be collected and analysed as part of this study to draw conclusions concerning the effectiveness and acceptability of the Programme.

What are the benefits of participating?
In efforts to close the gap in women's research, SheMed is conducting this first of its kind clinical study around GLP-1 use in women. Our first 1,000 members will contribute to the cause through providing their anonymous data to help us and the greater population understand the benefits of GLP-1s on weight loss and beyond.
Another benefit for participating is weight loss, along with a reduction in the health complications often associated with obesity, such as heart disease, diabetes, and joint issues. We also hope to see a reduction in symptoms related to specific women's health conditions like PCOS (Polycystic Ovary Syndrome) and menopause. Participants will also receive continuous support throughout their journey to help ensure progress and safety.

Where is the study run from?
eMed Healthcare UK Ltd

When is the study starting and how long is it expected to run for?
December 2024 to December 2025

Who is funding the study?
eMed Healthcare UK Ltd

Who is the main contact?
E: support@shemed.com

The requirements to remain on our £99/month programme

Comprehensive screening kit with at-home blood collection

Weekly 60 second weigh-in calls to track your progress

Short monthly questionnaires as part of your treatment refill

Complimentary blood collection kits at 6 and 12 months

Please note:
  • During the 12-month programme the participant must complete three live check-ins in a four-week rolling period.
  • During the 12-month programme the participant must complete a refill questionnaire after their 3rd dose of each pen, in order for their next injection pen to be prescribed, so that they can stay on the programme. Delays to refill could impact the weekly check-in adherence requirement rules.
  • The participant must take three blood tests at the following stages:
    • As part of the initial eligibility process
    • After 6 months on the programme (complimentary)
    • After 12 months on the programme (complimentary)